Gilead Sciences
Company
The pharmaceutical company that acquired Kite Pharma for $11.9 billion in 2017, making anti-CD19 CAR T-cell therapy widely available.
Mentioned in 2 videos
Save the 2 videos on Gilead Sciences to your own pod.
Sign up free to keep building your knowledge base on Gilead Sciences as more episodes are added.
Videos Mentioning Gilead Sciences
177 - The development of cancer immunotherapy and its promise for treating advanced cancers
Peter Attia MD
The pharmaceutical company that acquired Kite Pharma for $11.9 billion in 2017, making anti-CD19 CAR T-cell therapy widely available.
E104: FTX collapse with Coinbase CEO Brian Armstrong + election results, macro update & more
All-In Podcast
A biopharmaceutical company, its stock performance is highlighted as an example of a defensive sector outperforming tech during the economic downturn.